Cogstate has rallied on the back of Aduhelm's FDA approval and the expected surge in study of Beta-amaloid drugs.

What you should know is that this wasnt a smooth process. In fact the FDA snubbed its own expert advisory committee.

Actually 10 of the 11 committee members voted against authorizing Aduhelm. The only other member abstained and then because the FDA went ahead anyway three committee members later resigned in protest.

This is crazy to me. There must be hidden motives and incentives driving this descision. It likely has set alzhiemer's research back many years as it careens into beta amyloid reducing agents that have shown no benefit.

How does this affect CGS? Well if a scandal is revealed or perhaps there is enough stink thrown up that any other agents with similar mechanism hit a brick wall on approval then the work will dry up just as quickly as it appeared with the approval.